Dr Reddy's Enters the Indian Trade Generics Market

Global pharmaceutical company Dr Reddy's Laboratories Ltd. today announced its entry into the trade generics business in India with the launch of its new dedicated division, "RGenX." Through this, the pharmaceutical company aims to give patients access to a broader range of products and a greater level of affordability. La nouvelle entreprise a l'intention de poursuivre le but de l'entreprise de rejoindre plus de 1,5 billion patients d'ici 2030. In India, Dr. Reddy's plans to introduce its commercial generics in all major cities and towns, including the countryside. To guarantee the availability of its products, the business will closely collaborate with its channel partners.

M.V. Ramana, Chief Executive Officer, India and Emerging Markets, said, "India is a key focus market for us. Today’s announcement is a continuation of our effort to build a well-rounded business in India. We continue to strengthen our branded generics business in India by growing brands, new product launches, productivity enhancement through digital and analytics, and select strategic acquisitions. We are exploring strategic collaborations in India and investing in innovative healthcare spaces that we see as future growth drivers. This foray into trade generics will add to our reach and depth by making high-quality medicines of Dr Reddy’s accessible to more patients around the country, in keeping with our purpose of ‘Good Health Can’t Wait’."